Alpha Tau Medical Ltd Stock Price, News & Analysis

Alpha Tau Medical (NASDAQ: DRTS) reported Q1 2025 financial results and significant clinical progress for its Alpha DaRT® cancer therapy. Key highlights include impressive interim results from pancreatic cancer trials with >90% disease control rate and positive safety profile. A combination trial with Keytruda® in head and neck cancer showed 75% systemic objective response rate and 37.5% complete response rate. The FDA approved IDEs for U.S. pilot studies in pancreatic cancer and glioblastoma. The company secured MDSAP certification for its Jerusalem facility and completed a $36.9 million financing with Oramed Pharmaceuticals. Financial results showed a net loss of $8.7 million ($0.12 per share) with cash position of $54.8 million as of March 31, 2025, further strengthened by the April financing.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, has appointed Nadav Kidron to its Board of Directors. Kidron, who currently serves as President, CEO, and Chairman of Oramed Pharmaceuticals, joins following a strategic investment between Alpha Tau and an Oramed affiliate. With extensive experience leading a public company in therapeutic innovation, Kidron brings valuable expertise as Alpha Tau progresses toward commercialization. His background includes leadership roles at MDG Real Estate Global, Israel Advanced Technology Industries Organization, and previous directorship at Entera Bio. Kidron holds an LL.B. and International MBA from Bar Ilan University.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced its CFO Raphi Levy's participation in two upcoming investor conferences in May 2025. Levy will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, from 3:30-4:00 PM ET in New York. Additionally, he will attend the Lytham Partners Spring 2025 Investor Conference virtually on May 29, 2025, for one-on-one meetings. Investors can schedule meetings with Mr. Levy at both conferences through their respective H.C. Wainwright and Lytham Partners representatives.

Alpha Tau Medical (NASDAQ: DRTS) has successfully closed a $36.9 million registered direct offering with Oramed Pharmaceuticals. The deal involves the sale of 14,110,121 ordinary shares at $2.612 per share to an Oramed affiliate.

The company plans to use the proceeds for general corporate purposes, including R&D for product candidates, manufacturing expansion, and potential commercialization efforts. Additionally, an Oramed affiliate will provide strategic services in investor and public relations over three years in exchange for payments and warrants for additional Alpha Tau shares.

The investment aligns with Alpha Tau's current growth phase, marked by four active U.S. trial approvals, expansion into multiple internal organ applications, manufacturing scale-up, and ongoing commercial preparations for their Alpha DaRT® alpha-radiation cancer therapy.

Alpha Tau Medical (NASDAQ: DRTS) has received FDA approval for an Investigational Device Exemption (IDE) to begin a pilot study treating recurrent glioblastoma (GBM) patients with their Alpha DaRT® technology. The trial will enroll up to 10 U.S. patients with recurrent GBM who are not candidates for surgery and have previously undergone central nervous system radiation.

The study's primary goal is to assess the feasibility and safety of the treatment, building on promising pre-clinical results. This approval follows the FDA's earlier Breakthrough Device Designation and acceptance into the FDA's Total Product Life Cycle Advisory Program, aimed at accelerating the Alpha DaRT treatment's path to market.

Glioblastoma is described as one of the most complex and treatment-resistant cancers, with an average survival rate of only 8 months, according to the National Brain Tumor Society.

Alpha Tau Medical (NASDAQ: DRTS) reported its full year 2024 financial results and corporate updates. The company's innovative Alpha DaRT cancer therapy showed promising interim results across multiple trials:

Key clinical highlights include high disease control rates in pancreatic cancer trials, and impressive response rates in combination with Keytruda for head and neck cancer treatment. The company received FDA approval for a U.S. pilot study combining Alpha DaRT with first-line chemotherapy for pancreatic cancer patients.

Financial results show:

• R&D expenses: $27.0M (vs $26.4M in 2023)
• Net loss: $31.8M or $0.45 per share (vs $29.2M in 2023)
• Cash position: $62.9M (vs $84.9M in 2023)

The company expects its current cash balance to fund operations for at least two years.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in upcoming investor conferences for March 2025. The company's CFO, Raphi Levy, will be presenting and available for one-on-one investor meetings.

Investors interested in scheduling meetings with Mr. Levy can coordinate through their representatives at Investor Summit Group, Oppenheimer, and Sidoti. The conferences represent an opportunity for investors to learn more about Alpha Tau's innovative cancer treatment technology and business developments.

Alpha Tau Medical (NASDAQ: DRTS) has achieved Medical Device Single Audit Program (MDSAP) certification for its Jerusalem manufacturing facility. This certification, established by regulatory authorities from Australia, Brazil, Canada, Japan, and the U.S., enables medical device manufacturers to undergo a single audit for ISO 13485 compliance and standards across these five markets.

The MDSAP certification may accelerate the commercialization timeline in participating countries through a streamlined auditing process. This achievement reflects Alpha Tau's commitment to quality, safety, and regulatory compliance while supporting the global expansion of their Alpha DaRT® alpha-radiation cancer therapy for solid tumors.

Alpha Tau Medical (NASDAQ: DRTS) has received FDA approval for an IDE supplement to expand its pilot trial of Alpha DaRT® cancer therapy. The expanded study will now include 30 total patients across two cohorts: patients with locally advanced pancreatic cancer and those with metastatic pancreatic cancer. This represents an increase from the previously announced 12-patient study examining Alpha DaRT combined with first-line chemotherapy in newly diagnosed metastatic pancreatic cancer patients.

The expanded trial will be conducted across up to 10 U.S. clinical trial sites, with each cohort consisting of 15 patients. This expansion follows recently released data showing positive results in disease control and overall survival for pancreatic cancer patients treated with Alpha DaRT.